flutiform®

Well-established EU performance and continued strong growth in Japan

flutiform® (fluticasone/formoterol) is a fixed dose combination of an inhaled anti-inflammatory (ICS) and a bronchodilator (LABA) in a pressurised meter dose inhaler (pMDI) device. Vectura earns revenue from product supply and royalties from in-market net sales, and is eligible to receive up to €30.0m in future sales milestones from Mundipharma. The product is now launched in 39 countries, and approved in a further nine.

£68.5m
Underlying revenue

37.6%
Gross profit margin

1 IMS MIDAS Q42017; *Units calculation equals to packs;Value at ex-manufacturer prices in LCUS$, CER Q42017.

Ultibro® Breezhaler® (Novartis, EU and RoW (excluding US))

In-market performance driving strong recurring revenue growth for Vectura

A first-in-class once-daily fixed dose inhaled dual bronchodilator (LAMA/LABA) indicated as a maintenance bronchodilator treatment to relieve the symptoms of adult patients with COPD.

£12.7m
Underlying revenue

100%
Gross profit margin

1 IMS MIDAS Q42017; *Units calculation equals to packs; Value at ex-manufacturer prices in LCUS$, CER Q42017.

OUR IN-MARKET PRODUCTS

  • Generic partnering
  • Enhanced delivery
  • Novel IP licensing

Seebri® Breezhaler®

(EU and RoW – launched 2012)

Seebri™ Neohaler®

(US – launched late 2017)

  • Partner: Novartis
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Easy to use DPI device and effective bronchodilator (LAMA).

AirFluSal® Forspiro®

(EU and RoW, ex. US – launched 2014)

  • Partner: Sandoz
  • Capability: Sweet spot
  • Category: Generic partnering
Details
Asthma and COPD
Anti-inflammatory and bronchodilator (ICS/LABA) delivered using Vectura’s proprietary Gyrohaler® DPI device is a cost-effective alternative to Seretide® and/or other ICS/LABA treatments.

BreelibTM

(EU and ROW, ex. US – launched in 2017)

  • Partner: Bayer
  • Capability: Device and development
  • Category: Vectura enhanced therapies
Details
Pulmonary arterial hypertension
Vectura’s proprietary handheld FOX® nebuliser used to deliver Bayer’s iloprost solution – delivery technology reduces mean inhalation time to three minutes per treatment meaning that a typical patient’s inhalation time is reduced by 48 minutes.

Relvar® Ellipta®/Breo® Ellipta®

(Global)
Launched 2013 (US and RoW)
Launched 2014 (EU)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
Asthma/COPD
Once-daily anti-inflammatory and bronchodilator (ICS/LABA) which utilises Vectura’s formulation IP.

Incruse® Ellipta®

(Global)
Launched 2014 (RoW)
Launched 2015 (US and EU)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Once-daily bronchodilator (LAMA) which utilises Vectura’s formulation IP.

Anoro® Ellipta®

(Global)
Launched 2014 (US, EU and RoW)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Once-daily dual bronchodilator (LAMA/LABA) which utilises Vectura’s formulation IP.

Seebri® Breezhaler®

(EU and RoW – launched 2012)

Seebri™ Neohaler®

(US – launched late 2017)

  • Partner: Novartis
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Easy to use DPI device and effective bronchodilator (LAMA).

Relvar® Ellipta®/Breo® Ellipta®

(Global)
Launched 2013 (US and RoW)
Launched 2014 (EU)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
Asthma/COPD
Once-daily anti-inflammatory and bronchodilator (ICS/LABA) which utilises Vectura’s formulation IP.

AirFluSal® Forspiro®

(EU and RoW, ex. US – launched 2014)

  • Partner: Sandoz
  • Capability: Sweet spot
  • Category: Generic partnering
Details
Asthma and COPD
Anti-inflammatory and bronchodilator (ICS/LABA) delivered using Vectura’s proprietary Gyrohaler® DPI device is a cost-effective alternative to Seretide® and/or other ICS/LABA treatments.

Incruse® Ellipta®

(Global)
Launched 2014 (RoW)
Launched 2015 (US and EU)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Once-daily bronchodilator (LAMA) which utilises Vectura’s formulation IP.

BreelibTM

(EU and ROW, ex. US – launched in 2017)

  • Partner: Bayer
  • Capability: Device and development
  • Category: Vectura enhanced therapies
Details
Pulmonary arterial hypertension
Vectura’s proprietary handheld FOX® nebuliser used to deliver Bayer’s iloprost solution – delivery technology reduces mean inhalation time to three minutes per treatment meaning that a typical patient’s inhalation time is reduced by 48 minutes.

Anoro® Ellipta®

(Global)
Launched 2014 (US, EU and RoW)

  • Partner: GSK
  • Capability: Formulation
  • Category: Novel molecule partnering
Details
COPD
Once-daily dual bronchodilator (LAMA/LABA) which utilises Vectura’s formulation IP.